Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H31N3OS.2C4H4O4 |
Molecular Weight | 641.732 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CCCC(=O)C1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCN(C)CC4)C=C1
InChI
InChIKey=WVYWSPZQGQMPKW-SPIKMXEPSA-N
InChI=1S/C24H31N3OS.2C4H4O4/c1-3-7-22(28)19-10-11-24-21(18-19)27(20-8-4-5-9-23(20)29-24)13-6-12-26-16-14-25(2)15-17-26;2*5-3(6)1-2-4(7)8/h4-5,8-11,18H,3,6-7,12-17H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6126230 |
|||
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
211 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1990 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2860932/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUTAPERAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (co-administration study) Comment: Coadministration of Desipramine (CYP2D6 substrate) increased Butaperazine concentration. |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
22VUW43J2H
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
m2789
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
6433234
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697826
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
213-900-5
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
C76440
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
1063-55-4
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
100000084858
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY | |||
|
SUB00913MIG
Created by
admin on Fri Dec 15 15:06:46 GMT 2023 , Edited by admin on Fri Dec 15 15:06:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD